I am a board-certified associate attending physicist in the Radiation Dosimetry section of the Department of Medical Physics. I earned my PhD in radiation physics from University College London, specializing in volumetric-modulated arc therapy. I joined the Department of Medical Physics after graduating from MSK’s postdoctoral fellowship and residency program in 2012.
My responsibilities include quality assurance (QA) of our radiation therapy treatment units, and the development and implementation of new QA techniques. I am also involved in commissioning new machinery and software integral to treatment planning for patients. In addition to my clinical duties, I devote time to teaching and mentoring medical physics residents.
Through my research, I continually work to find ways to improve treatment efficiency and accuracy, and am particularly focused on enhancing real-time motion-adaptive radiation therapy for prostate, lung, and gastrointestinal diseases.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Grace Tang discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
View all disclosures